Back to Awarded Treatment Trials


Awarded Trial: 03T-413

Grant ID

03T-413

Illness

Schizophrenia

Primary Drug/Intervention

L-carnosine

Primary Dosage

up to 2000 mg/day

Secondary Drug Intervention

N/A

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Chengappa

Sample Size

84

Duration of Study Period for Each Subject

4 months

Outcome Measurements

Cognitive battery, PANSS, CGI, CDS, quality of life scales

Results

In a double-blind trial, 75 patients with schizophrenia were randomized to L-carnosine, 2000 mg/d, for 3 months and assessed on a variety of cognitive tests. Patients on L-carnosine showed significant improvement on some tests of executive function, specifically set shifting and strategic target detection tests.

Publication

Chengappa KNR, Turkin SR, DeSanti S, Bowie CR, Brar JS, Schlicht PJ, Murphy SL, Hetrick ML, Bilder R, Fleet D. A preliminary, randomized, double-blind, placebo-controlled trial of L-carnosine to improve cognition in schizophrenia. Schizophr Res. 2012 Dec;142(1-3):145-52.

Link

http://www.ncbi.nlm.nih.gov/pubmed/23099060

PI Name

Kadiamada Chengappa

Degree

MD

Center

Western Psychiatric Institute and Clinic

Institution

University of Pittsburgh Medical Center

Address

3811 O'Hara Street

City or Town

Pittsburgh

State or Province

PA

Zip or Postal Code

15213

Country

USA

Email Address

chengappakn@msx.upmc.edu